Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Glatiramer Acetate During Pregnancy

Is it safe?

Publish date:: January 19, 2016

Glatiramer acetate exposure during the first trimester of pregnancy appears safe and without teratogenic effect, according to a study comparing the outcomes of pregnancies in 151 women with MS exposed to glatiramer acetate and 95 women with MS unexposed to disease modifying therapies during pregnancy. Researchers found:

3 (2.2%) congenital anomalies occurred in the exposed group vs 6 (6.7%) in the control group.

No increase was seen in other adverse pregnancy or delivery outcomes including spontaneous abortions, preterm birth, Caesarian sections, or reduced birth weight in the exposed group.

Citation: Herbstritt S, Langer-Gould A, Rockhoff M, et al. Glatiramer acetate during early pregnancy: A prospective cohort study. [Published online ahead of print January 11, 2016]. Mult Scler. doi:10.1177/1352458515623366.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Multiple Sclerosis

Long-term safety and efficacy of teriflunomide for relapsing MS,

Newer DMTs are more effective than injectable DMTs in pediatric MS,

Neutrophil granulocyte markers may distinguish between demyelinating diseases,

Bacteria may be associated with risk of MS relapse,

Women with MS may have increased subclinical disease activity during pregnancy,